The Economic and Public Health Imperatives Around Making Potential Coronavirus Disease-2019 Treatments Available and Affordable

Value Health. 2020 Nov;23(11):1427-1431. doi: 10.1016/j.jval.2020.04.1824. Epub 2020 May 21.

Authors

Steven Forsythe¹, Joshua Cohen², Peter Neumann³, Stefano M Bertozzi⁴, Anthony Kinghorn⁵

Affiliations

¹ Avenir Health, Glastonbury, CT, USA. Electronic address: sforsythe@avenirhealth.org.
² Joshua P. Cohen Healthcare Analytics, Boston, MA, USA.
³ Tufts Medical Center, Boston, MA, USA.
⁴ University of California Berkeley School of Public Health, Berkeley, CA, USA; Instituto Nacional de Salud Pública, Cuernavaca, México; University of Washington, Seattle, WA, USA.
⁵ Perinatal HIV Research Unit, University of the Witwatersrand, Soweto, South Africa.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Betacoronavirus
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections* / drug therapy
Coronavirus*
Humans
Lopinavir
Pandemics*
Pneumonia, Viral*
Public Health
Ritonavir
SARS-CoV-2

Substances

Lopinavir
Ritonavir